Indicator Bacteria Concentrations of Two Northwest Arkansas Streams in Relation to Flow and Season

Concentrations of indicator bacteria such as fecal coliform (FC) and fecal streptococcus (FS) are often used to assess the suitability of waters for their intended use(s) and to allocate resources for water quality improvement measures. There is evidence, however, that concentrations of FC and FS can be influenced by variables such as season and flow rate during sampling, which could lead to biased results. The objective of this study was to assess the impacts of season and flow rate on concentrations of FC and FS. Fecal indicator bacteria concentrations were measured for approximately three years at five sites on two Northwest Arkansas streams. Flow data were collected at two of the five sites. Land use in the basins draining the streams was primarily pasture (57-90%) and forest (6-40%). Significant seasonal influences on FC and FS concentrations were detected for all sampling sites, with the highest concentrations occurring in summer. On the two sites with flow data, flow rate generally had a significant effect on FC and FS concentrations during all seasons, with FC and FS concentrations increasing with flow rate. Ratios of FC and FS, which have been used in the past to differentiate between animal and human sources of fecal pollution, did not appear to reliably indicate the major sources of fecal indicator bacteria. The findings of this study suggest a potential for fixed sampling intervals to contribute to biased results. The issue of biased results might be avoided by sampling during times of year and flow conditions that support the intended use(s) of the waters

Chemistry, temperature, and faunal distributions at diffuse-flow hydrothermal vents : comparison of two geologically distinct ridge systems

Author Posting. © The Oceanography Society, 2012. This article is posted here by permission of The Oceanography Society for personal use, not for redistribution. The definitive version was published in Oceanography 25, no. 1 (2012): 234–245, doi:10.5670/oceanog.2012.22.Diffuse-flow, low-temperature areas near hydrothermal vents support life via chemosynthesis: hydrogen sulfide (and other reduced chemical compounds) emanating from the subsurface is oxidized with bottom-water oxygen through bacterial mediation to fix carbon dioxide and produce biomass. This article reviews the in situ diffuse-flow chemistry (mainly H2S and O2) and temperature data collected in 2006 and 2009 along the Eastern Lau Spreading Center (ELSC), and from 2004 to 2008 at 9°N along the East Pacific Rise (9 N EPR), predominantly around macrofauna that contain endosymbionts at these two hydrothermal vent regions. More than 48,000 and 20,000 distinct chemical and temperature data points were collected with a multi-analyte electrochemical analyzer in the diffuse-flow waters at 9 N EPR and the ELSC, respectively. Despite their different geological settings and different macrofauna (two different species of snails and mussels at the ELSC versus two different species of tubeworms and mussels at 9 N EPR), there are similarities in the temperature and chemistry data, as well as in the distributions of organisms. The pattern of water chemistry preferred by the provannid snails (Alviniconcha spp., Ifremeria nautilei) and Bathymodiolus brevior at the ELSC is similar to the water chemistry pattern found for the siboglinid tubeworms (Tevnia jerichonana, Riftia pachyptila) and the Bathymodiolus thermophilus mussels at 9 N EPR. The eruptions at 9 N EPR in 2005 and 2006 resulted in increased H2S concentrations, increased H2S/T ratios, and an initial change in the dominant tubeworm species from Riftia pachyptila to Tevnia jerichonana after the eruption created new vent habitats. In 2005, two sites at 9 N EPR showed major increases in the H2S/T ratio from 2004, which suggested a probable eruption in this basalt-dominated system. At the ELSC, there was a decrease in the H2S/T ratio from northern to southern sites, which reflects the change in geological setting from basalt to andesite and the shallower water depths at the southern sites.This work was supported by NSF grants OCE-0240896, OCE-073243 (ELSC), OCE-0308398 (OTIC), OCE-0326434, and OCE-0937324 (EPR) to GWL; ESI-0087679, OCE-9529819, and OCE-0327353 to RAL; OCE-0327261, OCE-0328117, OCE-0451983 to TMS; and OCE 0240985 and OCE 0732333 to CRF

Functions of height and width dimensions in the intertidal mussel, Mytilus californianus

Author Posting. © National Shellfisheries Association, 2008. This article is posted here by permission of National Shellfisheries Association for personal use, not for redistribution. The definitive version was published in Journal of Shellfish Research 27 (2008): 385-392, doi:10.2983/0730-8000(2008)27[385:FOHAWD]2.0.CO;2.A mussel's shell records its history of growth. We investigated variability in the size and shape of mussel shells of Mytilus californianus Conrad (1837) to test the hypothesis that the mussel shell provides information on the contemporary condition of the mussel. Two factors were associated with shape: an epithelial discoloration and the Sr/Ca in the shell nacre. Sr/Ca data distinguished the mussel populations as did a discriminate analysis that included the trace metal ratios; Sr/Ca, Mg/Ca, Mn/Ca, Ag/Ca, Cd/Ca, Ba/Ca, and Pb/Ca. Size varied independently of shape and was not associated with the two factors. However, a null model that describes the morphological variability in height and width suggests that mussel size also plays a central role in partitioning phenotypic variability. These analyses of contemporary factors coupled with analyses of morphological variability holds promise for addressing the functional roles of mussel height and width and what proportion of phenotypic variability can be attributed to environmental factors

Galaxy Zoo: CANDELS barred discs and bar fractions

The formation of bars in disc galaxies is a tracer of the dynamical maturity of the population. Previous studies have found that the incidence of bars in discs decreases from the local Universe to z ~ 1, and by z > 1 simulations predict that bar features in dynamically mature discs should be extremely rare. Here, we report the discovery of strong barred structures in massive disc galaxies at z ~ 1.5 in deep rest-frame optical images from the Cosmic Assembly Near-Infrared Deep Extragalactic Legacy Survey. From within a sample of 876 disc galaxies identified by visual classification in Galaxy Zoo, we identify 123 barred galaxies. Selecting a subsample within the same region of the evolving galaxy luminosity function (brighter than L*), we find that the bar fraction across the redshift range 0.5 ≤ z ≤ 2 (fbar = 10.7+6.3 -3.5 per cent after correcting for incompleteness) does not significantly evolve.We discuss the implications of this discovery in the context of existing simulations and our current understanding of the way disc galaxies have evolved over the last 11 billion yearsPeer reviewedFinal Accepted Versio

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19. METHODS: The COV-BOOST trial is a multicentre, blinded, phase 2, randomised controlled trial of seven COVID-19 vaccines given as third-dose boosters at 18 sites in the UK. This sub-study enrolled participants who had received BNT162b2 (Pfizer-BioNTech) as their third dose in COV-BOOST and randomly assigned them (1:1) to receive a fourth dose of either BNT162b2 (30 μg in 0·30 mL; full dose) or mRNA-1273 (Moderna; 50 μg in 0·25 mL; half dose) via intramuscular injection into the upper arm. The computer-generated randomisation list was created by the study statisticians with random block sizes of two or four. Participants and all study staff not delivering the vaccines were masked to treatment allocation. The coprimary outcomes were safety and reactogenicity, and immunogenicity (anti-spike protein IgG titres by ELISA and cellular immune response by ELISpot). We compared immunogenicity at 28 days after the third dose versus 14 days after the fourth dose and at day 0 versus day 14 relative to the fourth dose. Safety and reactogenicity were assessed in the per-protocol population, which comprised all participants who received a fourth-dose booster regardless of their SARS-CoV-2 serostatus. Immunogenicity was primarily analysed in a modified intention-to-treat population comprising seronegative participants who had received a fourth-dose booster and had available endpoint data. This trial is registered with ISRCTN, 73765130, and is ongoing. FINDINGS: Between Jan 11 and Jan 25, 2022, 166 participants were screened, randomly assigned, and received either full-dose BNT162b2 (n=83) or half-dose mRNA-1273 (n=83) as a fourth dose. The median age of these participants was 70·1 years (IQR 51·6-77·5) and 86 (52%) of 166 participants were female and 80 (48%) were male. The median interval between the third and fourth doses was 208·5 days (IQR 203·3-214·8). Pain was the most common local solicited adverse event and fatigue was the most common systemic solicited adverse event after BNT162b2 or mRNA-1273 booster doses. None of three serious adverse events reported after a fourth dose with BNT162b2 were related to the study vaccine. In the BNT162b2 group, geometric mean anti-spike protein IgG concentration at day 28 after the third dose was 23 325 ELISA laboratory units (ELU)/mL (95% CI 20 030-27 162), which increased to 37 460 ELU/mL (31 996-43 857) at day 14 after the fourth dose, representing a significant fold change (geometric mean 1·59, 95% CI 1·41-1·78). There was a significant increase in geometric mean anti-spike protein IgG concentration from 28 days after the third dose (25 317 ELU/mL, 95% CI 20 996-30 528) to 14 days after a fourth dose of mRNA-1273 (54 936 ELU/mL, 46 826-64 452), with a geometric mean fold change of 2·19 (1·90-2·52). The fold changes in anti-spike protein IgG titres from before (day 0) to after (day 14) the fourth dose were 12·19 (95% CI 10·37-14·32) and 15·90 (12·92-19·58) in the BNT162b2 and mRNA-1273 groups, respectively. T-cell responses were also boosted after the fourth dose (eg, the fold changes for the wild-type variant from before to after the fourth dose were 7·32 [95% CI 3·24-16·54] in the BNT162b2 group and 6·22 [3·90-9·92] in the mRNA-1273 group). INTERPRETATION: Fourth-dose COVID-19 mRNA booster vaccines are well tolerated and boost cellular and humoral immunity. Peak responses after the fourth dose were similar to, and possibly better than, peak responses after the third dose. FUNDING: UK Vaccine Task Force and National Institute for Health Research

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial

OBJECTIVES: To evaluate the persistence of immunogenicity three months after third dose boosters. METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose. The analysis was conducted using all randomised participants who were SARS-CoV-2 naïve during the study. RESULTS: Among the 2883 participants randomised, there were 2422 SARS-CoV-2 naïve participants until D84 visit included in the analysis with median age of 70 (IQR: 30-94) years. In the participants who had two initial doses of ChAd, schedules using mRNA vaccines as third dose have the highest anti-spike IgG at D84 (e.g. geometric mean concentration of 8674 ELU/ml (95% CI: 7461-10085) following ChAd/ChAd/BNT). However, in people who had two initial doses of BNT there was no significant difference at D84 in people given ChAd versus BNT (geometric mean ratio (GMR) of 0.95 (95%CI: 0.78, 1.15). Also, people given Ad26.COV2.S (Janssen; hereafter referred to as Ad26) as a third dose had significantly higher anti-spike IgG at D84 than BNT (GMR of 1.20, 95%CI: 1.01,1.43). Responses at D84 between people who received BNT (15 μg) or BNT (30 μg) after ChAd/ChAd or BNT/BNT were similar, with anti-spike IgG GMRs of half-BNT (15 μg) versus BNT (30 μg) ranging between 0.74-0.86. The decay rate of cellular responses were similar between all the vaccine schedules and doses. CONCLUSIONS: 84 days after a third dose of COVID-19 vaccine the decay rates of humoral response were different between vaccines. Adenoviral vector vaccine anti-spike IgG concentration at D84 following BNT/BNT initial doses were higher than for a three dose (BNT/BNT/BNT) schedule. Half dose BNT immune responses were similar to full dose responses. While high antibody tires are desirable in situations of high transmission of new variants of concern, the maintenance of immune responses that confer long-lasting protection against severe disease or death is also of critical importance. Policymakers may also consider adenoviral vector, fractional dose of mRNA, or other non-mRNA vaccines as third doses

Genomic investigations of unexplained acute hepatitis in children

Since its first identification in Scotland, over 1000 cases of unexplained pediatric hepatitis in children have been reported worldwide, including 278 cases in the UK 1. Here we report investigation of 38 cases, 66 age-matched immunocompetent controls and 21 immunocompromised comparator subjects, using a combination of genomic, transcriptomic, proteomic and immunohistochemical methods. We detected high levels of adeno-associated virus 2 (AAV2) DNA in liver, blood, plasma or stool from 27/28 cases. We found low levels of Adenovirus (HAdV) and Human Herpesvirus 6B (HHV-6B), in 23/31 and 16/23 respectively of the cases tested. In contrast, AAV2 was infrequently detected at low titre in blood or liver from control children with HAdV, even when profoundly immunosuppressed. AAV2, HAdV and HHV-6 phylogeny excluded emergence of novel strains in cases. Histological analyses of explanted livers showed enrichment for T-cells and B-lineage cells. Proteomic comparison of liver tissue from cases and healthy controls, identified increased expression of HLA class 2, immunoglobulin variable regions and complement proteins. HAdV and AAV2 proteins were not detected in the livers. Instead, we identified AAV2 DNA complexes reflecting both HAdV and HHV-6B-mediated replication. We hypothesize that high levels of abnormal AAV2 replication products aided by HAdV and in severe cases HHV-6B, may have triggered immune-mediated hepatic disease in genetically and immunologically predisposed children